Healthcare Industry News: Edwards Lifesciences
News Release - October 16, 2008
CoreValve Wins Patent Infringement Action in GermanyIRVINE, Calif.--(HSMN NewsFeed)--CoreValve (www.corevalve.com) announced today that it has prevailed in a patent infringement lawsuit with Edwards Lifesciences in Germany.
The decision by the German Federal Court found that CoreValve’s ReValving® system for transcatheter aortic valve replacement does not infringe any of the claims of the Andersen patent held by Edwards. This ruling protects CoreValve’s rights to continue its expanded clinical evaluation of its proprietary system for percutaneous aortic valve replacement in high-risk patients with advanced aortic valve disease in Germany.
“We are pleased that the German court, after a comprehensive review of the evidence provided by both companies, found that CoreValve’s ReValving system does not infringe the Andersen patent. We will continue to vigorously defend our own intellectual property and our legal right to continue to develop and clinically evaluate our ReValving system for the treatment of patients worldwide,” said Daniel Lemaitre, CoreValve’s President and Chief Executive Officer.
CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company’s Web site at www.corevalve.com.
(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.